home / stock / akba / akba articles
Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (C...
Shares of RH (NYSE: RH) rose sharply in today’s pre-market trading following the release of quarterly results. RH posted weaker-than-expecte...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday. Shares of Cintas Corporation (NASDAQ: CTAS) rose sharply ...
HC Wainwright has upgraded Akebia Therapeutics Inc (NASDAQ: AKBA) from Neutral to Buy rating. Analysts Ed Arce ...
Covered a research piece on Akebia Therapeutics, a biopharmaceutical developing cutting-edge therapies for the treatment of patients with kidney diseases.
News, Short Squeeze, Breakout and More Instantly...
Akebia Therapeutics Inc. Company Name:
AKBA Stock Symbol:
NASDAQ Market:
Akebia Therapeutics Inc. Website:
Akebia Therapeutics to Present at the 2nd Annual HCW Bioconnect Investor Conference PR Newswire CAMBRIDGE, Mass. , May 14, 2024 /PRNewswire/ -- Akebia Therapeutics ® , Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to b...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...